文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

心房颤动与射血分数降低、轻度降低和保留的心衰不良结局风险:系统评价和荟萃分析。

Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis.

机构信息

Boston University Chobanian and Avedisian School of Medicine, Boston, USA.

VA Providence Healthcare System, Providence, Rhode Island, USA.

出版信息

J Cardiovasc Electrophysiol. 2024 Apr;35(4):715-726. doi: 10.1111/jce.16209. Epub 2024 Feb 13.


DOI:10.1111/jce.16209
PMID:38348517
Abstract

INTRODUCTION: Heart failure (HF) and atrial fibrillation (AF) frequently co-exist. Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF). Aggregate data comparing the risk profile of AF between these three HF categories are lacking. METHODS: We conducted a systematic review and meta-analysis aimed at determining any significant differences in AF-associated all-cause mortality, HF hospitalizations, cardiovascular mortality (CV), and stroke between HFrEF, HFmrEF, and HFpEF. A systematic search of PubMed, EMBASE, and Cochrane Library databases until February 28, 2023. Data were combined using DerSimonian-Laird random effects model. RESULTS: A total of 22 studies comprising 248 323 patients were retained: HFrEF 123 331 (49.7%), HFmrEF 40 995 (16.5%), and HFpEF 83 997 (33.8%). Pooled baseline AF prevalence was 36% total population, 30% HFrEF, 36% HFmrEF, and 42% HFpEF. AF was associated with a higher risk of all-cause mortality in the total population with pooled hazard ratio (HR) = 1.13 (95% confidence interval [CI] = 1.07-1.21), HFmrEF (HR = 1.25, 95% CI = 1.05-1.50) and HFpEF (HR = 1.16, 95% CI = 1.09-1.24), but not HFrEF (HR = 1.03, 95% CI = 0.93-1.14). AF was associated with a higher risk of HF hospitalizations in the total population (HR = 1.29, 95% CI = 1.14-1.46), HFmrEF (HR = 1.64, 95% CI = 1.20-2.24), and HFpEF (HR = 1.46, 95% CI = 1.17-1.83), but not HFrEF (HR = 1.01, 95% CI = 0.87-1.18). AF was only associated with CV in the HFpEF subcategory but was associated with stroke in all three HF subtypes. CONCLUSIONS: AF appears to be associated with a higher risk of all-cause mortality and HF hospitalization in HFmrEF and HFpEF. With these findings, the paucity of data and treatment guidelines on AF in the HFmrEF subgroup becomes even more significant and warrant further investigations.

摘要

简介:心力衰竭(HF)和心房颤动(AF)经常同时存在。当代 HF 的分类将其分为射血分数降低的 HF(HFrEF)、射血分数轻度降低的 HF(HFmrEF)和射血分数保留的 HF(HFpEF)。缺乏比较这三种 HF 类别中 AF 风险特征的综合数据。

方法:我们进行了一项系统评价和荟萃分析,旨在确定 HFrEF、HFmrEF 和 HFpEF 之间 AF 相关全因死亡率、HF 住院、心血管死亡率(CV)和卒中的任何显著差异。对 PubMed、EMBASE 和 Cochrane Library 数据库进行了系统检索,截至 2023 年 2 月 28 日。使用 DerSimonian-Laird 随机效应模型合并数据。

结果:共纳入 22 项研究,共 248323 例患者:HFrEF 123331 例(49.7%)、HFmrEF 40995 例(16.5%)和 HFpEF 83997 例(33.8%)。总人群的基线 AF 患病率为 36%,HFrEF 为 30%,HFmrEF 为 36%,HFpEF 为 42%。AF 与总人群的全因死亡率风险增加相关,合并危险比(HR)=1.13(95%置信区间[CI] = 1.07-1.21),HFmrEF(HR = 1.25,95% CI = 1.05-1.50)和 HFpEF(HR = 1.16,95% CI = 1.09-1.24),但 HFrEF 无相关性(HR = 1.03,95% CI = 0.93-1.14)。AF 与总人群 HF 住院风险增加相关(HR = 1.29,95% CI = 1.14-1.46)、HFmrEF(HR = 1.64,95% CI = 1.20-2.24)和 HFpEF(HR = 1.46,95% CI = 1.17-1.83),但 HFrEF 无相关性(HR = 1.01,95% CI = 0.87-1.18)。AF 仅与 HFpEF 亚组的 CV 相关,但与所有三种 HF 亚型的卒中相关。

结论:AF 似乎与 HFmrEF 和 HFpEF 中的全因死亡率和 HF 住院风险增加相关。这些发现表明,HFmrEF 亚组中关于 AF 的数据和治疗指南非常匮乏,这一点更加明显,需要进一步研究。

相似文献

[1]
Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis.

J Cardiovasc Electrophysiol. 2024-4

[2]
Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.

JACC Heart Fail. 2017-7-12

[3]
Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction.

Heart. 2020-8

[4]
Prognosis and treatment strategies for atrial fibrillation in heart failure with mildly reduced ejection fraction.

Eur J Prev Cardiol. 2024-8-22

[5]
Outcomes of Atrial Fibrillation Ablation in Heart Failure Subtypes.

Circ Arrhythm Electrophysiol. 2024-9

[6]
Prevalence and Prognostic Implication of Atrial Fibrillation in Heart Failure Subtypes: Systematic Review and Meta-Analysis.

Heart Lung Circ. 2023-6

[7]
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.

Eur J Heart Fail. 2022-6

[8]
Systematic review and meta-analysis of stroke and thromboembolism risk in atrial fibrillation with preserved vs. reduced ejection fraction heart failure.

BMC Cardiovasc Disord. 2024-9-18

[9]
Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction.

J Interv Card Electrophysiol. 2019-9

[10]
Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.

Eur Heart J. 2018-12-21

引用本文的文献

[1]
Predictors of Atrial Fibrillation in Heart Failure Patients with Indications for ICD Implantation.

J Clin Med. 2025-6-18

[2]
Analysis of Grip Strength Thresholds for Stroke Management and Prevention in South Korean Older Adults.

Healthcare (Basel). 2025-3-31

[3]
Atrial Fibrillation Recurrence Post-Ablation Across Heart Failure Categories: A Systematic Review and Meta-analysis.

Cardiol Res. 2025-2

[4]
Heart failure with preserved ejection fraction and atrial fibrillation: epidemiology, pathophysiology, and diagnosis interplay.

Heart Fail Rev. 2025-1-24

[5]
Disease Network-Based Approaches to Study Comorbidity in Heart Failure: Current State and Future Perspectives.

Curr Heart Fail Rep. 2024-12-27

[6]
Efficacy of Sacubitril/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation.

Cureus. 2024-10-19

[7]
Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium-Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the "Middle Child of HF"? Real-World Experience from a Single Clinical Centre.

J Cardiovasc Dev Dis. 2024-5-31

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索